Table 3.
Treatment with glucose‐lowering drug before switching to GLP‐1RAs (Pre) and in addition to GLP‐1RAs during the observation study (basal, 1 y, 2 y)
| Cohort | Sulphonylureas/repaglinide (%) | Pioglitazone (%) | Basal insulin (%) | DPP‐4Is (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Timea | Pre | Basal | 1‐y | 2‐y | Pre | Basal | 1‐y | 2‐y | Pre | Basalb | Preb |
| GLP‐1RA + SC | 43.7 | 31.7 | 29.5 | 25.0 | 9.3 | 5.9 | 7.7 | 7.3 | 19.1 | 14.2 | 9.9 |
| GLP‐1RA + ENE | 45.5 | 22.7 | 18.2 | 4.8 | 14.3 | 13.7 | 13.7 | 9.5 | 9.1 | 9.1 | 4.5 |
| GLP‐1RA + CBT | 40.9 | 25.0 | 22.7 | 29.3 | 2.3 | 2.3 | 4.7 | 2.5 | 22.7 | 11.6 | 4.5 |
| Total | 43.4 | 29.8 | 27.3 | 23.9c | 8.9c | 6.3 | 7.7 | 7.3 | 18.9 | 13.3 | 8.4 |
Abbreviations: CBT, cognitive‐behavioural treatment; ENE, elementary nutritional education.
A number of cases are as follows: GLP‐1RA + SC, 244 (Pre and basal), 199 (1 y) and 119 (2 y); GLP‐1RA + ENE, 29, 22 and 15; GLP‐1RA + CBT, 53, 43 and 27, respectively.
Basal insulin was maintained in association with GLP‐1RAs in all cases, although at variable doses; DPP4‐Is were always stopped at time of switch to GLP‐1RA treatment; metformin was used in nearly all cases (excluding intolerant patients) at standard doses of 2000‐2550 mg/d.
The analysis indicates heterogeneity of use among groups (Chi2, P value <0.05).